Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Affordable Ozempic is on the way, presenting both advantages and challenges for Australians - The Age

13 Apr, 2026

FDA Greenlights Foundayo, a New Oral Weight-Loss Medication Similar to Ozempic - ColombiaOne.com

13 Apr, 2026

Novo Nordisk A/S shares (DK0062498333): Can the leading position in obesity medications lead to significant growth?

13 Apr, 2026

Affordable Ozempic is on the way, presenting both advantages and challenges for Australians - SMH

13 Apr, 2026